COAG Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. (COAG) is expected to report earnings on February 9, 2027, before the market open. The consensus earnings estimate is a loss of $0.59 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.3% since its last earnings release on November 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.